Scleroderma

Patient Data Presented at 2023 EULAR Congress Highlights How Serum CCL24 Levels Can Predict Vascular and Fibrotic Complications of Systemic Sclerosis

Retrieved on: 
Friday, June 2, 2023
CCL24, University, Therapy, Serum, European Alliance of Associations for Rheumatology, CMMB, ILD, Prognosis, Primary sclerosing cholangitis, Scleroderma, Doctor of Philosophy, TEL, Incidence, Congress, Patient, European, DSM-IV codes, Risk, Poster, R, EULAR, European Alliance, Systemic scleroderma, Disease, Pharmaceutical industry, Rheumatology

MILAN and TEL AVIV, Israel, June 2, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced a poster presentation at the 2023 European Congress of Rheumatology, hosted by the European Alliance of Association for Rheumatology (EULAR) and held in Milan, Italy May 31–June 3, 2023.

Key Points: 
  • The poster, "CCL24 serum concentration predicts both vascular and fibrotic complications in systemic sclerosis," was presented today by Professor Enrico De Lorenzis of the Leeds Institute of Rheumatic and Musculoskeletal Diseases at the University of Leeds in the UK.
  • The study was conducted by Professor De Lorenzis and his colleagues who enrolled systemic sclerosis (SSc) patients from an observational cohort and compared them with age- and gender-matched controls.
  • 1 - CCL24 serum concentration predicts both vascular and fibrotic complications in systemic sclerosis, Enrico De Lorenzis, Adi Mor, Rebecca Ross, Stefano Di Donato, Revital Aricha, Hilit Levi, Ilan Vaknin, Francesco Del Galdo
    A copy of the poster will be available at the R&D portion of Chemomab's website.
  • For more information on the EULAR Congress, visit https://congress.eular.org/

AnaMar Announces Positive Phase I Data for its Phase II Ready Compound AM1476 for Treating Fibrosis

Retrieved on: 
Tuesday, May 23, 2023
Therapy, Disability, ILD, Organ dysfunction, Biomarker, Scleroderma, Interstitial lung disease, Lung, EMA, Fibrosis, Vital capacity, Patient, CGMP, FDA, Death, Systemic scleroderma, Skin, Disease, Pharmaceutical industry, Research

LUND, Sweden, May 23, 2023 (GLOBE NEWSWIRE) -- AnaMar, a clinical-stage biotech company developing a first-in-class, peripheral 5-HT2B receptor antagonist, AM1476, as a pan anti-fibrotic medicine, announces positive results from its Phase I study, and the completion of Phase II enabling pre-clinical studies for its initial orphan indication in systemic sclerosis (SSc) characterized by lung and skin fibrosis.

Key Points: 
  • Skin fibrosis is a leading feature of SSc associated with significant disability.
  • The degree of skin fibrosis provides insight about progression of the disease.
  • Active product ingredients are being made ready as cGMP materials for this Phase II trial.
  • The company is planning regulatory submissions, in 2023, to the FDA and EMA for Orphan Drug Designation for the rare disease SSc.

Global Scleroderma Therapeutics Market Report 2023: Availability of a Range of Treatment Options Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 24, 2023
Health, Pharmaceutical, Tissue, Heart, Therapy, Prevalence, Human, Scar, Cyclophosphamide, Methotrexate, Research, Calcium channel, Inflammation, USD, Blood, ACE, Scleroderma, Autoimmune disease, Immune system, Organic acid, Agent handling, Collagen, Skin, Disease, Pharmaceutical industry

The "Global Scleroderma Therapeutics Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Scleroderma Therapeutics Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.
  • The value of the global scleroderma therapeutics market was USD 1.92 billion in 2022, driven by increasing prevalence of scleroderma, rising awareness about the disease across the globe.
  • The global scleroderma therapeutics market is driven by the increasing prevalence of scleroderma, rising awareness about the disease, and the availability of a range of treatment options.
  • The report gives an in-depth analysis of the key players involved in the global scleroderma therapeutics market.

Chemomab Therapeutics to Participate in Upcoming Scientific Conferences

Retrieved on: 
Wednesday, May 24, 2023
CCL24, EASL, Therapy, NASH, Liver, CMMB, Inflammation, Scleroderma, European Congress of Radiology, Doctor of Philosophy, Fibrosis, TEL, Congress, Patient, European Association for the Study of the Liver, EULAR, PSC, Systemic scleroderma, Primary sclerosing cholangitis, Pharmaceutical industry, Rheumatology

TEL AVIV, Israel, May 24, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced upcoming CM-101 data presentations at major European scientific conferences in June 2023, including EULAR23, the European Congress of Rheumatology, and EASL 2023, the Annual Congress of the European Association for the Study of the Liver.

Key Points: 
  • TEL AVIV, Israel, May 24, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced upcoming CM-101 data presentations at major European scientific conferences in June 2023, including EULAR23, the European Congress of Rheumatology, and EASL 2023, the Annual Congress of the European Association for the Study of the Liver.
  • Further details of the presented data will be forthcoming.
  • "Our poster presentations at EULAR and EASL highlight the novelty and potential of our unique approach to fibro-inflammatory diseases," said Dale Pfost, PhD, CEO of Chemomab.
  • EULAR23 – European Congress of Rheumatology – Milan, Italy, May 31-June 3, 2023

CUMBERLAND PHARMACEUTICALS ANNOUNCES FDA CLEARANCE OF IND FOR NEW TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS

Retrieved on: 
Tuesday, May 23, 2023
Idiopathic pulmonary fibrosis, Clinical trial, Duchenne muscular dystrophy, Pulmonary fibrosis, Patient, Scleroderma, FDA, IPF, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Food, Safety, Pharmaceutical industry

NASHVILLE, Tenn., May 23, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq:CPIX) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for a Phase II study in patients with Idiopathic Pulmonary Fibrosis, the most common form of progressive fibrosing interstitial lung disease. As a result, Cumberland will launch its FIGHTING FIBROSIS trial designed to enroll 128 patients in over 20 medical centers of excellence across the U.S.

Key Points: 
  • Cumberland initiating Phase II FIGHTING FIBROSIS™ clinical trial,
    NASHVILLE, Tenn., May 23, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq:CPIX) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for a Phase II study in patients with Idiopathic Pulmonary Fibrosis, the most common form of progressive fibrosing interstitial lung disease.
  • The Company has designed a Phase II clinical trial to study the safety, tolerability, and efficacy of oral ifetroban in patients with IPF.
  • Recent studies have shown ifetroban can both prevent and enhance resolution of lung fibrosis in multiple preclinical models.
  • Cumberland previously received IND clearance from the FDA for several indications including Systemic Sclerosis and Duchenne Muscular Dystrophy.

aTyr Pharma Announces First Quarter 2023 Results and Provides Corporate Update

Retrieved on: 
Tuesday, May 9, 2023
Sarcoidosis, University, Small RNA, ATyr Pharma, Concept, ATS, Granuloma, Connective tissue, Clinical trial, ILD, Research, Scleroderma, American Thoracic Society, International Conference on Nuclear Disarmament, Oslo, 2008, Patient, Investment, SAN, Fibrosis, Systemic scleroderma, Vasculitis, Safety, Conference, D.C, D, Pharmaceutical industry, Bank, Communications satellite, Medicine

Phase 2 proof-of-concept study of efzofitimod in patients with SSc-ILD expected to initiate in the third quarter of 2023.

Key Points: 
  • Phase 2 proof-of-concept study of efzofitimod in patients with SSc-ILD expected to initiate in the third quarter of 2023.
  • Ended the first quarter 2023 with $117.6 million in cash, cash equivalents and investments.
  • SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced first quarter 2023 results and provided a corporate update.
  • G&A Expenses: General and administrative expenses were $3.4 million for the first quarter 2023.

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2023 Financial Results

Retrieved on: 
Monday, May 8, 2023
Queensland University of Technology, Clinical trial, Patient, Security (finance), University of Queensland, Safety, Pharmaceutical industry, Cryptocurrency, Netherton syndrome, Quoin, Scleroderma

ASHBURN, Va., May 08, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today provides a business update and announces financial results for the first quarter of 2023.

Key Points: 
  • Quoin CEO, Dr. Michael Myers, said, “We are very pleased to announce a very positive start to 2023, which has the potential to be a transformational year for Quoin.
  • In February 2023, Quoin completed a public offering of securities with net proceeds of approximately $5.8 million, which Quoin expects to extend the company’s cash runway into 2H 2024.
  • Quoin had approximately $17.0 million in cash, cash equivalents and marketable securities as of March 31, 2023.
  • Net loss for the quarter ended March 31, 2023 was approximately $2.6 million compared to approximately $1.7 million for the quarter ended March 31, 2022.

BioMed X Launches XSeed Labs in the US with Boehringer Ingelheim - a New Model for Building an External Innovation Ecosystem on an Industry Campus

Retrieved on: 
Thursday, April 27, 2023
Yale University, NASH, Boehringer Ingelheim, Biomedical Research, Research, Fibrosis, Crohn's disease, Patient, BioMed Central, Fatty liver disease, Ecosystem, Scleroderma, Wound healing, Medical imaging

RIDGEFIELD, CT, Apr 27, 2023 - (ACN Newswire) - BioMed X announced today the expansion of its collaboration with Boehringer Ingelheim with the launch of a new model for biomedical research: XSeed Labs.

Key Points: 
  • RIDGEFIELD, CT, Apr 27, 2023 - (ACN Newswire) - BioMed X announced today the expansion of its collaboration with Boehringer Ingelheim with the launch of a new model for biomedical research: XSeed Labs.
  • The first research project of the new lab will focus on fibrotic disease processes, a key focus area of Boehringer Ingelheim.
  • The goal of this new collaboration is to bring BioMed X's successful innovation model to Boehringer Ingelheim's main US research and development campus and serve as a nucleus for a vibrant external innovation ecosystem.
  • Dr. Christian Tidona, Founder and Managing Director of BioMed X, explains: "The principle behind BioMed X has always been to combine the best of both worlds - academia and industry.

Ocean Biomedical (NASDAQ: OCEA) Announces Notice of Allowance for U.S. Patent Application for Breakthrough Pulmonary Fibrosis Treatments Issued to Scientific Co-founder Dr. Jack A. Elias.

Retrieved on: 
Thursday, April 20, 2023
Yale University, Patent, Kidney failure, Ocean Biomedical, Idiopathic pulmonary fibrosis, Therapy, Prevalence, NASH, Critical Care Medicine (journal), RI, United States Patent and Trademark Office, University, Survival, Dean, Yale New Haven Hospital, Research, Asbestosis, Pulmonary fibrosis, Pharmacotherapy, Fibrosis, HPS, Science, Silicosis, Patient, Chandos Chair of Medicine and Anatomy, Hermansky–Pudlak syndrome, Brown University, IPF, Alcoholic liver disease, IND, Biology, Scleroderma, Pharmaceutical industry, Medicine

This patent allowance covers pulmonary fibrosis caused by multiple conditions including: idiopathic pulmonary fibrosis (IPF), genetic pulmonary fibrosis such as Hermansky-Pudlak Syndrome (HPS), chemotherapy and radiation-induced pulmonary fibrosis, and exposure-induced interstitial lung diseases including asbestosis and silicosis.

Key Points: 
  • This patent allowance covers pulmonary fibrosis caused by multiple conditions including: idiopathic pulmonary fibrosis (IPF), genetic pulmonary fibrosis such as Hermansky-Pudlak Syndrome (HPS), chemotherapy and radiation-induced pulmonary fibrosis, and exposure-induced interstitial lung diseases including asbestosis and silicosis.
  • A Notice of Allowance is issued after the USPTO examines a patent application and determines that the applicant should be granted a patent from the application.
  • Ocean Biomedical anticipates that a patent will be issued by the USPTO from Dr. Elias’ application in the coming months.
  • In four pulmonary fibrosis animal models, Ocean Biomedical’s OCF-203 has shown an 85% – 90% reduction in collagen accumulation.

$134 Million in Financial Backing for Innovative Research and IND Fillings Announced by Ocean Biomedical (NASDAQ: OCEA); Provides Latest Updates on Advancement of Platform, Novel Discoveries in Malaria, Pulmonary Fibrosis and Oncology

Retrieved on: 
Monday, April 17, 2023
Prevalence, CHI3L1, Ng, Doctor of Philosophy, Patent, Risk, Hermansky–Pudlak syndrome, Disease, Glioblastoma, Laboratory, DSM-IV codes, GBM, NASH, RI, Research, Infection, Brain, Pulmonary fibrosis, Growth, Alcoholic liver disease, IND, NIH, Metastasis, Idiopathic pulmonary fibrosis, Common stock, Parasitism, Ocean Biomedical, United States Patent and Trademark Office, Cancer, Lung cancer, NSCLC, Vaccine, Fibrosis, Science, Tuberculosis, Times Square, Non-small-cell lung cancer, Stanford University School of Medicine, University, Lung, HPS, Health, Scleroderma, Renewable energy, Pharmaceutical industry, Dietary supplement, MD, Malaria

Ocean visited the Nasdaq MarketSite in Times Square to ring the Opening Bell in its debut as a public company.

Key Points: 
  • Ocean visited the Nasdaq MarketSite in Times Square to ring the Opening Bell in its debut as a public company.
  • “We’re immensely pleased with the progress we’re making as a Company,” said Elizabeth Ng, Ocean’s CEO.
  • With the support of Ocean, these innovations can be more quickly delivered to those that desperately need them.
  • Moreover, the company’s drug target discovery platform can potentially discover targets against other infectious diseases, like tuberculosis or another pandemic-type virus.